Epigenomics AG (EPGNF)
USD 0.79
(0.0%)
USD 0.79
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 282.31 Thousand EUR | -22.65% |
| 2022 | 365 Thousand EUR | -93.98% |
| 2021 | 6.06 Million EUR | 770.44% |
| 2020 | 697 Thousand EUR | -20.07% |
| 2019 | 872 Thousand EUR | -20.22% |
| 2018 | 1.09 Million EUR | -32.45% |
| 2017 | 1.61 Million EUR | -36.97% |
| 2016 | 2.56 Million EUR | 183.02% |
| 2015 | 907 Thousand EUR | 16.88% |
| 2014 | 776 Thousand EUR | -29.52% |
| 2013 | 1.1 Million EUR | 47.39% |
| 2012 | 747 Thousand EUR | -30.83% |
| 2011 | 1.08 Million EUR | -17.75% |
| 2010 | 1.31 Million EUR | -10.19% |
| 2009 | 1.46 Million EUR | 64.64% |
| 2008 | 888 Thousand EUR | -72.38% |
| 2007 | 3.21 Million EUR | -50.12% |
| 2006 | 6.44 Million EUR | 238.55% |
| 2005 | 1.9 Million EUR | -12.38% |
| 2004 | 2.17 Million EUR | -60.04% |
| 2003 | 5.43 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 FY | 282.31 Thousand EUR | -22.65% |
| 2023 Q4 | 61.15 Thousand EUR | 0.0% |
| 2023 Q2 | 65 Thousand EUR | -32.29% |
| 2023 Q1 | 96 Thousand EUR | 31.51% |
| 2023 Q3 | 61.15 Thousand EUR | -5.91% |
| 2022 Q3 | 109 Thousand EUR | 14.74% |
| 2022 Q1 | 89 Thousand EUR | -35.04% |
| 2022 Q4 | 73 Thousand EUR | -33.03% |
| 2022 FY | 365 Thousand EUR | -93.98% |
| 2022 Q2 | 95 Thousand EUR | 6.74% |
| 2021 Q3 | 5.75 Million EUR | 6224.18% |
| 2021 Q4 | 137 Thousand EUR | -97.62% |
| 2021 FY | 6.06 Million EUR | 770.44% |
| 2021 Q1 | 83 Thousand EUR | -69.26% |
| 2021 Q2 | 91 Thousand EUR | 9.64% |
| 2020 FY | 697 Thousand EUR | -20.07% |
| 2020 Q3 | 176 Thousand EUR | 158.82% |
| 2020 Q1 | 182 Thousand EUR | -20.52% |
| 2020 Q2 | 68 Thousand EUR | -62.64% |
| 2020 Q4 | 270 Thousand EUR | 53.41% |
| 2019 FY | 872 Thousand EUR | -20.22% |
| 2019 Q1 | 238 Thousand EUR | 260.61% |
| 2019 Q2 | 276 Thousand EUR | 15.97% |
| 2019 Q3 | 129 Thousand EUR | -53.26% |
| 2019 Q4 | 229 Thousand EUR | 77.52% |
| 2018 Q3 | 416 Thousand EUR | 23.44% |
| 2018 FY | 1.09 Million EUR | -32.45% |
| 2018 Q1 | 274 Thousand EUR | -70.66% |
| 2018 Q2 | 337 Thousand EUR | 22.99% |
| 2018 Q4 | 66 Thousand EUR | -84.13% |
| 2017 FY | 1.61 Million EUR | -36.97% |
| 2017 Q1 | 251 Thousand EUR | -84.44% |
| 2017 Q3 | 273 Thousand EUR | 70.63% |
| 2017 Q2 | 160 Thousand EUR | -36.25% |
| 2017 Q4 | 934 Thousand EUR | 242.12% |
| 2016 Q2 | 426 Thousand EUR | 61.98% |
| 2016 FY | 2.56 Million EUR | 183.02% |
| 2016 Q4 | 1.61 Million EUR | 508.68% |
| 2016 Q3 | 265 Thousand EUR | -37.79% |
| 2016 Q1 | 263 Thousand EUR | -1.13% |
| 2015 Q3 | 163 Thousand EUR | -32.08% |
| 2015 Q4 | 266 Thousand EUR | 63.19% |
| 2015 Q2 | 240 Thousand EUR | 0.84% |
| 2015 Q1 | 238 Thousand EUR | 64.14% |
| 2015 FY | 907 Thousand EUR | 16.88% |
| 2014 Q1 | 210 Thousand EUR | -54.55% |
| 2014 FY | 776 Thousand EUR | -29.52% |
| 2014 Q4 | 145 Thousand EUR | -21.62% |
| 2014 Q3 | 185 Thousand EUR | -21.94% |
| 2014 Q2 | 237 Thousand EUR | 12.86% |
| 2013 Q2 | 227 Thousand EUR | -6.97% |
| 2013 Q3 | 168 Thousand EUR | -25.99% |
| 2013 Q4 | 462 Thousand EUR | 175.0% |
| 2013 FY | 1.1 Million EUR | 47.39% |
| 2013 Q1 | 244 Thousand EUR | 7.49% |
| 2012 Q2 | 131 Thousand EUR | -32.47% |
| 2012 FY | 747 Thousand EUR | -30.83% |
| 2012 Q1 | 194 Thousand EUR | 39.57% |
| 2012 Q3 | 193 Thousand EUR | 47.33% |
| 2012 Q4 | 227 Thousand EUR | 17.62% |
| 2011 FY | 1.08 Million EUR | -17.75% |
| 2011 Q1 | 472 Thousand EUR | -2.07% |
| 2011 Q2 | 264 Thousand EUR | -44.07% |
| 2011 Q3 | 204 Thousand EUR | -22.73% |
| 2011 Q4 | 139 Thousand EUR | -31.86% |
| 2010 Q1 | 451 Thousand EUR | 62.82% |
| 2010 Q4 | 482 Thousand EUR | 186.9% |
| 2010 Q3 | 168 Thousand EUR | -20.38% |
| 2010 Q2 | 211 Thousand EUR | -53.22% |
| 2010 FY | 1.31 Million EUR | -10.19% |
| 2009 Q3 | 586 Thousand EUR | 90.26% |
| 2009 FY | 1.46 Million EUR | 64.64% |
| 2009 Q1 | 291 Thousand EUR | 0.0% |
| 2009 Q2 | 308 Thousand EUR | 5.84% |
| 2009 Q4 | 277 Thousand EUR | -52.73% |
| 2008 FY | 888 Thousand EUR | -72.38% |
| 2007 FY | 3.21 Million EUR | -50.12% |
| 2006 FY | 6.44 Million EUR | 238.55% |
| 2005 FY | 1.9 Million EUR | -12.38% |
| 2004 FY | 2.17 Million EUR | -60.04% |
| 2003 FY | 5.43 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Bio Medica Corporation | -193 Thousand USD | 246.277% |
| Arrayit Corporation | 2.57 Million USD | 89.037% |
| Atlantic International Corp. | -154.23 Thousand USD | 283.043% |
| Biocept, Inc. | -2.58 Million USD | 110.934% |
| Bioqual, Inc. | 7.42 Million USD | 96.2% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 276 Thousand USD | -2.288% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 6.73 Billion USD | 99.996% |
| HTG Molecular Diagnostics, Inc. | 1.79 Million USD | 84.264% |
| iMD Companies, Inc. | -23.63 Thousand USD | 1294.377% |
| IDenta Corp. | 662.97 Thousand USD | 57.417% |
| Interpace Biosciences, Inc. | 23.04 Million USD | 98.775% |
| Integrative Health Technologies, Inc. | 77.57 Thousand USD | -263.944% |
| InVitro International | 635.98 Thousand USD | 55.61% |
| Lumos Diagnostics Holdings Limited | 6.56 Million USD | 95.698% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 1.09 Million USD | 74.163% |
| NovelStem International Corp. | 12 Thousand USD | -2252.625% |
| Optigenex Inc. | -102.96 Thousand USD | 374.183% |
| PharmChem, Inc. | 3.9 Million USD | 92.769% |
| Proteome Sciences plc | 2.09 Million USD | 86.535% |
| Response Genetics, Inc | 3.94 Million USD | 92.838% |
| Rennova Health, Inc. | 6.26 Million USD | 95.496% |
| RushNet, Inc. | 1.1 Million USD | 74.442% |
| ScreenPro Security Inc. | 856.57 Thousand USD | 67.041% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | -403.74 Thousand USD | 169.924% |
| Todos Medical Ltd. | 4.31 Million USD | 93.45% |